PMDA drug package insert
デプロメール錠25
PMDA Prescription drug · Meiji Seika ファルマ株式会社 · package insert Nov 16, 2022
Key facts
| Brand names | デプロメール錠25, デプロメール錠50, デプロメール錠75 |
|---|---|
| Nonproprietary names | フルボキサミンマレイン酸塩 |
| Companies | 製造販売元／Meiji Seika ファルマ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 選択的セロトニン再取り込み阻害剤（SSRI） |
| Therapeutic category codes | 871179 |
| YJ codes | 1179039F1028, 1179039F2024, 1179039F3020 |
| Approval numbers | 21100AMZ00429000, 21100AMZ00430000, 22000AMX00966000 |
| Package insert edition | 第5版 |
| Package insert date | Nov 16, 2022 |
| PMDA document key | 780009_1179039F1028_1 |
| PMDA company code | 780009 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: